What Happens When You Stop Ozempic, Wegovy or Zepbound: Weight Regain, Explained

When you stop semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro), your appetite comes back and, on average, so does a good part of the weight you lost. In the STEP 1 extension, people who had lost an average of 17.3% on semaglutide regained about two-thirds of it over the following year. In SURMOUNT-4, people switched from tirzepatide to placebo gained 14.0% in 52 weeks, while those who stayed on it lost another 5.5%. These are averages with a lot of variation: in an analysis of that same trial among people who had lost at least 10%, 17.5% regained less than a quarter of what they had lost.

The drug facts here come from the US prescribing information for Wegovy, Ozempic, Zepbound and Mounjaro. In this guide I explain why regain happens, what’s linked to regaining less and what to bring to your next appointment. It isn’t a guide to stopping treatment: that decision belongs to you and the person who prescribes it.

Why your appetite comes back when you stop

The drug leaves your body, but not overnight

These medications curb hunger while they’re in your bloodstream. After the last dose, they take weeks to clear, according to the labels:

Drug	Half-life (time for the level in your blood to fall by half)	What the label says about clearance
Semaglutide (Wegovy)	About 1 week	Present in the circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or the last 25 mg tablet
Semaglutide (Ozempic)	About 1 week	Present in the circulation for about 5 weeks after the last dose
Tirzepatide (Zepbound)	About 5 to 6 days in people with overweight or obesity	The US label gives no time-in-circulation figure
Tirzepatide (Mounjaro)	About 5 days	The US label gives no figure; the EU prescribing information says to stop it at least 1 month before a planned pregnancy because of the long half-life

Sources: US labels for Wegovy, Ozempic, Zepbound and Mounjaro (section 12.3); EU prescribing information for Mounjaro (section 4.6).

That’s why the effect on appetite is expected to fade gradually, not from one day to the next.

Your body defends the weight you lost

The second reason has nothing to do with the drug. When you lose weight, the hormones that regulate appetite change, and those changes last. Sumithran and colleagues (2011) studied 50 people with overweight or obesity, without diabetes, who lost an average of 13.5 kg (29.8 lb) on a 10-week very-low-calorie diet. A year later, leptin (the hormone that signals fat stores), peptide YY and cholecystokinin (two fullness signals) were still lower than at the start. Ghrelin, which stimulates hunger, was still higher. And the hunger participants reported was still greater.

That study didn’t use a GLP-1, but it helps explain the problem: stopping the drug removes the brake on appetite just as the body is pushing back toward its previous weight.

What the withdrawal trials show

Trial	Participants	What happened after stopping the drug	Time off the drug
STEP 1 extension (semaglutide)	327 adults without diabetes; the lifestyle program was withdrawn too	Regained 11.6 percentage points of the 17.3% lost; net loss of 5.6% from the start (placebo group: 0.1%)	52 weeks
STEP 4 (semaglutide)	803 adults without diabetes, randomized after 20 weeks of treatment (10.6% average loss)	+6.9% on placebo vs. −7.9% for those who continued (difference −14.8 points; 95% CI −16.0 to −13.5)	48 weeks
SURMOUNT-4 (tirzepatide)	670 adults without diabetes, randomized after 36 weeks (20.9% average loss)	+14.0% on placebo vs. −5.5% for those who continued (difference −19.4 points; 95% CI −21.2 to −17.7)	52 weeks

95% CI: 95% confidence interval, the range where the true effect probably lies. The US labels report the same STEP 4 and SURMOUNT-4 results, as Study 5 in the Wegovy label and Study 4 in the Zepbound label.

Three details that often get overlooked:

• In STEP 4 and SURMOUNT-4, everyone kept getting diet and physical activity counseling, and they still regained weight. The 2025 joint advisory from four US medical and nutrition societies (I’ll call it “the advisory”) notes that regain has been seen even with nutrition counseling or behavioral therapy.
• On average, people didn’t return to their starting weight within that time. In SURMOUNT-4, total loss from the start of the trial was 9.9% in the placebo group and 25.3% on tirzepatide. For STEP 4, the EU prescribing information for Wegovy states that the observed mean body weight at week 68 was still lower than at the start of the run-in period; the US label shows the data but doesn’t say it in words.
• The manufacturers funded these trials (Novo Nordisk and Eli Lilly), they excluded people with diabetes, and the STEP 1 extension is an exploratory analysis.

Not everyone regains the same amount

The post hoc analysis of SURMOUNT-4 (done afterward, using data already collected) looked at 308 people who had lost at least 10% on tirzepatide and were switched to placebo. A year later, this is how the regain broke down:

Share of lost weight regained	People	Percentage
Less than 25%	54	17.5%
25% to under 50%	77	25.0%
50% to under 75%	103	33.4%
75% or more	74	24.0%

Most people regained at least a quarter, but the paths were very different.

Blood pressure, blood sugar and cholesterol follow the weight

In that analysis, waist size went up an average of 0.8 cm (0.3 in) in people who regained less than 25% and 14.7 cm (5.8 in) in those who regained 75% or more. Systolic blood pressure rose by 6.8 to 10.4 mm Hg, and HbA1c (a measure of average blood sugar over the past few months) by 0.14 to 0.35 points. The STEP 1 extension saw something similar: most cardiometabolic improvements drifted back toward baseline.

What the meta-analyses say

• West and colleagues, BMJ, 2026. Across 37 studies with 9,341 participants, weight came back at an average of 0.4 kg (0.9 lb) a month. With the newer incretin drugs, such as semaglutide and tirzepatide, it was 0.8 kg (1.8 lb) a month, and the model projects a return to starting weight at around 1.5 years. Regain was faster than after lifestyle programs without medication.
• Budini and colleagues, eClinicalMedicine, 2026. Pooling 6 randomized trials (3,236 participants), 60% of the lost weight had come back at one year. Extrapolating, the curve would level off at around 75.3% (95% CI 68.9 to 81.6), below starting weight.

The projections differ because they use different models and go beyond the observed data. Both describe fast regain after stopping; Budini’s model also predicts that it slows over time.

This isn’t a personal failure

The authors of the STEP 1 extension conclude that their data confirm obesity is a chronic disease and that keeping the improvements appears to require ongoing treatment. It’s the same logic as with high blood pressure: if a treatment works while you take it, you’d expect the effect to fade when it’s withdrawn.

Regaining weight after stopping the drug doesn’t show a lack of willpower. It reflects biology pushing in that direction. And weight is only one part of health: blood pressure, blood sugar, strength and sleep count too.

What’s linked to regaining less weight

The evidence here is thinner than I’d like. This is what there is:

• Supervised exercise. This is the most interesting direct evidence. In a Danish trial, adults who had lost 13.1 kg (28.9 lb) on a diet spent a year on maintenance with supervised exercise, liraglutide (an older GLP-1 medication), both, or placebo. In the year after that ended, those who had taken liraglutide alone regained 6.0 kg (13.2 lb) more than those who had exercised (95% CI 2.1 to 10.0 kg), who kept their weight. It’s small (109 people in the follow-up) and didn’t use semaglutide or tirzepatide.
• A lot of physical activity. The American College of Sports Medicine (ACSM) position stand reports that, after weight loss, keeping it off is associated with more than 250 minutes a week of moderate activity. But it cautions that these data are observational: no well-designed trials confirm it.
• Protein and strength training. The advisory recommends strength training at least three times a week plus 150 minutes of aerobic activity, mainly to preserve muscle and bone. I go deeper in protein and muscle on GLP-1 medications. It’s plausible that protecting muscle reduces regain after stopping, but it hasn’t been proven.
• Behavioral support. According to the advisory, structured nutrition support after stopping a GLP-1 hasn’t been tested in controlled trials. And the BMJ meta-analysis found that the intensity of support during treatment didn’t change the pace of regain. That doesn’t mean support is useless, only that we don’t yet know how much it helps.
• Gradual dose reduction versus stopping all at once. I haven’t found randomized trials with published results. The REST trial, with semaglutide, is studying this. Until there’s data, it’s an open question, and any change to your dosing schedule is your prescriber’s call.

A maintenance plan to discuss with your prescriber

None of this replaces the medication or guarantees a result. These are habits with reasonable support that are worth having in place before any change:

• Enough protein at every meal. The advisory cites 0.8 g per kilogram a day (0.36 g per pound) for the general population and 1.2 to 1.6 g/kg (0.54 to 0.73 g per pound) during active weight loss. For someone who weighs 154 lb (70 kg), that’s 56 g and 84 to 112 g. You can estimate your own number with the protein calculator (in Spanish, in kilograms) and go over it with your healthcare professional, especially if you have kidney disease.
• Strength training at least 2 days a week. That’s the WHO minimum for adults, working all major muscle groups, along with 150 to 300 minutes a week of moderate aerobic activity. Free weights, resistance bands or your own body weight all work.
• Meal structure. Regular meal times, fiber and planned meals can help when hunger returns. My guide to what to eat on GLP-1 medications has ideas for each phase, including stopping treatment.
• Self-monitoring, only if it doesn’t cause distress. The advisory links long-term maintenance with tracking your weight, food and activity. But if stepping on the scale makes you anxious or makes your relationship with food worse, set it aside and talk to your doctor or a registered dietitian.
• Sleep. The advisory notes that poor sleep is associated with more hunger and weight gain, and it includes sleep in the assessment of people on GLP-1 medications.
• Follow-up with your prescriber. Agree on when to check in, what change in weight or symptoms would justify an earlier visit, and whether other medications might need adjusting.

Who shouldn’t make this decision alone

No one, really. But in some cases there are specific medical reasons to talk it through first:

• Type 2 diabetes. Semaglutide and tirzepatide also lower blood sugar. The US labels say that when starting these drugs, prescribers should consider reducing the dose of insulin or of an insulin secretagogue such as a sulfonylurea to lower the risk of hypoglycemia. Stopping the GLP-1 can shift that balance, and adjusting the rest of your treatment is your doctor’s job.
• Cardiovascular disease. The SELECT trial enrolled 17,604 adults with existing cardiovascular disease and overweight or obesity, without diabetes. During treatment, over an average follow-up of 39.8 months, semaglutide lowered major cardiovascular events from 8.0% to 6.5%. In the US, the Wegovy label includes reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight as an indication. I haven’t found data showing that this benefit continues after stopping.
• Planning a pregnancy. The US Wegovy and Ozempic labels say to stop semaglutide at least 2 months before a planned pregnancy because of its long half-life. For tirzepatide, the Zepbound label says to discontinue it when pregnancy is recognized, and the EU prescribing information for Mounjaro adds stopping it at least 1 month before a planned pregnancy. It’s worth raising with your doctor well ahead of time.
• Warning symptoms. All four US labels say to discontinue the drug if pancreatitis is suspected. The EU prescribing information for semaglutide also says to stop it if NAION (non-arteritic anterior ischemic optic neuropathy, damage to the optic nerve) is confirmed after a sudden loss of vision; the current US labels don’t include that warning. If you have severe, persistent abdominal pain or a sudden loss of vision, contact your doctor or go to the emergency room the same day: they’re the ones who decide what happens with your treatment.

Frequently asked questions

Do you regain all the weight?

On average, not in the first year: a year after stopping, weight was still 5.6% below the starting point in the STEP 1 extension and 9.9% below it in SURMOUNT-4. But most people regain a substantial share, and the longer-term models disagree on whether weight eventually returns to where it started.

How long does it take to leave your body?

According to the US labels, semaglutide stays in the circulation for about 5 to 7 weeks after the last dose of Wegovy and about 5 weeks after the last dose of Ozempic. Tirzepatide’s half-life is about 5 days (5 to 6 days in people with overweight or obesity, per the Zepbound label). That’s why appetite is expected to come back gradually.

Can you start again?

It’s an option your prescriber can weigh with you, but I haven’t found published trials that measure what happens when people restart after a long break. The US labels describe a stepwise start with dose increases to reduce the risk of gastrointestinal adverse reactions. If you restart, how and when is your doctor’s decision. My guides to nausea and constipation on GLP-1 medications cover what to eat during those first weeks.

Does lowering the dose gradually prevent weight regain?

We don’t know yet. I haven’t found published randomized trials comparing a gradual withdrawal with an abrupt one; the REST trial is studying it. Any change in dose is your prescriber’s decision.

Is the rebound bigger with Zepbound or Mounjaro than with Ozempic or Wegovy?

I haven’t found trials that compare them head to head after withdrawal. On placebo, weight went up 14.0% in SURMOUNT-4 (tirzepatide) and 6.9% in STEP 4 (semaglutide), but after different amounts of prior weight loss and different treatment lengths, so the numbers aren’t comparable.

Do blood pressure, blood sugar and cholesterol come back too?

Largely, yes, and in proportion to the weight regained. In SURMOUNT-4, people who regained less than a quarter of their lost weight kept their improvements in waist size, non-HDL cholesterol and fasting insulin. If you have high blood pressure, diabetes or high cholesterol, ask your doctor how to keep an eye on them if your treatment changes.